Doctors Without Borders is urging wider use of Merck & Co.’s Ebola vaccine in the Democratic Republic of Congo to combat the escalating Bundibugyo outbreak. The group cites emerging evidence suggesting the vaccine, originally designed for the Zaire strain, may offer protection against the Bundibugyo virus.
Ervebo, the vaccine in question, is already being tested against the Bundibugyo virus and has been administered to thousands under research and compassionate-use programs. However, current restrictions limit its broader deployment.
The medical aid organization is pushing for these restrictions to be lifted, arguing that more people at risk, including young children, should be able to receive the vaccine. The call comes as the outbreak continues to worsen.